Select Page ::

Gene Expression Analysis Market to Surge at a Robust Pace in Terms of Revenue over COVID-19 Crisis 2018 2026 – Kentucky Journal 24

Posted on September 6, 2020 by Danzig

Global gene expression analysis market was valued US$ 4.2 Bn in 2017 and is expected to reach US$ 8.6 Bn by 2026, at a CAGR of 9.37 % during a forecast period.

Gene expression is a procedure of deriving information from a gene to synthesize a functional gene product. Rising use of gene expression analysis in precision medicine provides key opportunities for the market during the forecast period.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/6087

Falling cost of sequencing, technological advancements, increasing the prevalence of cancer, and availability of government funding are propelling the market growth. Novel technologies to aid gene expression studies, rising application areas of gene expression, and availability of gene expression databases are boosting the growth the global gene expression analysis market. Currency Devaluation is a major challenge of the market. The high cost of instruments and lack of trained professionals are hindering the market growth.

The growing volume of genetic tests in drug & biomarker discovery and pharmacogenomics applications are driving the growth of the consumables market. The rising installation of NGS & PCR tools worldwide will significantly boost the demand for consumables. PCR analysis is estimated to the largest revenue share owing to high adoption & introduction of systems integrated with other steps as well as techniques.

Pharmaceutical & biotechnology companies utilize gene expression analysis products & services to achieve their clinical research goals like drug discovery & development and biotech research. The high volume of research studies involving gene expression analysis and huge capital for high-end analysis instruments & consumables is expected to grow at the highest rate during the forecast period in the pharmaceutical and biotechnology segment.

The Asia Pacific market is expected to grow at the highest rate during the forecast period owing to the domestic manufacturing of sequencing systems, western partnerships to improve healthcare, high R&D intensity, government focus on cancer and other life science research, and flourishing bioresearch centers.

Key player operating in global gene expression analysis market are Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche, GE Healthcare, Illumina, Inc., Oxford Gene Technology, Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., and Thermo Fisher Scientific, Inc.

The Scope of Global Gene Expression Analysis Market:

Global Gene Expression Analysis Market, by Products & Services:

Consumables

Instruments

Services

Global Gene Expression Analysis Market, by End User:

Pharmaceutical & Biotech companies

Academic Institutes & Research Centers

Other End User

Global Gene Expression Analysis Market, by Region:

North America

Europe

Asia Pacific

South America

Middle East & Africa

Key Player Operating in Global Gene Expression Analysis Market:

Agena Bioscience

Applied Microarrays

Arrayit

AutoGenomics

Beijing Genomics Institute

BioChain Institute

Biometrix Technology

Cepheid

CombiMatrix

Danaher

Danyel Biotech

EMD Millipore

Eppendorf

Exiqon

Fluidigm

GE Healthcare

Great Basin

LC Sciences

Luminex

Microarrays

Miltenyi Biotec

OriGene Technologies

Oxford Gene Technology

Oxford Nanopore Technologies

Partek

Perkin Elmer

Phalanx Biotech Group

Promega

Takara Bio

Tecan

Veredus Laboratories

Zyagen.

More Info of Impact COVID-19@https://www.trendsmarketresearch.com/report/covid-19-analysis/6087

Read the original post:
Gene Expression Analysis Market to Surge at a Robust Pace in Terms of Revenue over COVID-19 Crisis 2018 2026 - Kentucky Journal 24

Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for…

Posted on September 11, 2020 by Danzig

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, the leader in comprehensive genetics and digital mental health services, has pioneered a new level of specificity and accuracy for cheek swab-based pharmacogenetics tests.

Genominds Professional PGx Express test provides clinicians with a comprehensive report of up to 24 genes that delivers important prescribing guidance designed to help reduce the traditional process of trial and error with mental health medications. Genomind has served over 15,000 clinicians and tested over 270,000 patients for this important treatment guidance. The FDA includes pharmacogenetic biomarker warnings, precautions and drug-drug interaction guidance on the labels of over 270 medications (https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling).

Two of the most important genetic variants which Genominds Professional PGx Express tests for are HLA-B *15:02 and HLA-A*31:01. These genes are part of the complex human leukocyte antigen (HLA) system that is among the most highly variable DNA regions in humans and is central to autoimmune diseases and transplant rejection. Both of these variants are associated with an increased risk of serious, sometimes fatal, skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, in the presence of carbamazepine (as well as oxcarbazepine and phenytoin for HLA-B*15:02).

Carbamazepine is indicated for the treatment of epilepsy and trigeminal neuralgia, and is commonly used for individuals with mood disorders, such as bipolar disorder. It is on the World Health Organizations List of Essential Medicines1 and was prescribed over 3.5 million times in 2019, a number that experts say will increase in 20202.

In contrast to HLA-B*15:02, the HLA-A* 31:01 allele is more common in Caucasians, while also occurring in individuals of Hispanic/South American and East Asian descent. Carbamazepines FDA label contains warnings about this gene-drug pair, as does the Clinical Pharmacogenetic Implementation Consortium (CPIC).

Until recently, commercial PGx assays commonly tested for this allele using a surrogate tag SNP (single nucleotide polymorphism) method. During a recent validation exercise, Genomind identified a very high false positive rate of approximately 40%, with this common industry method. This means with the traditional testing method, 40% of the positive tests would incorrectly identify someone as being at risk of serious adverse events with carbamazepine treatment, thereby inappropriately excluding a potentially useful agent.

Genominds CEO Shawn OBrien was inspired to find a better solution. Our company is all about our I-CAIRE culture (integrity, collaboration, accountability, innovation, respect and excellence), so when we discovered this shortcoming in the industry, we immediately set about finding a better solution to help more clinicians and patients.

Genomind scientists, led by CSO Dr. David Robbins, developed an innovative and proprietary real-time PCR (polymerase chain reaction) test that is highly specific for HLA-A*31:01. The increased specificity of this assay also makes the need for confirmatory testing unnecessary for individuals testing positive. In validation testing of this new and improved assay, specificity and sensitivity were 100%. In real-world testing we expect specificity to be >99%. This means we will be able to reduce the 40% of false positives down to a fraction of a percentage3. This PCR-based testing was validated by comparing random anonymized patient samples with HLA typing by Next Generation Sequencing (NGS) through a third party lab. FDA considers NGS as the gold standard for HLA typing. The validation was further supported by testing samples from the Coriell Institute for Medical Research with documented rare and common HLA-A types. Genomind filed a patent on this important breakthrough and is the only comprehensive mental health genetics test with this capability on the market.

This novel innovation uniquely provides much greater accuracy in identifying patients at risk for a serious drug reaction and provides greater and safer access of a potentially helpful medication, carbamazepine, for individuals previously thought to be at risk said Dr. Scott Aaronson, MD, Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association.

With Medicares recently published new Local Coverage Determination allowing coverage of tests like Genominds, and with United Healthcares positive coverage policy, the Mental Health PGx industry is expected to see major growth. Therefore, it is critical that clinicians have access to the most accurate and specific PGx results.

To this end Genomind is offering a major national digital education effort for clinicians and patients. They are starting with their 15,000 clinicians and providing education materials, access to their acclaimed On-Demand Hotline or scheduled consults, and free access to their state-of-the-art precision medication management software, G-DIG (Genomind Drug Interaction Guide.) Genomind will also be reaching tens of thousands of the highest prescribers of mental health medications and millions of potential patients with their digital communications engine that generates millions of hits and video views on their website annually. Genomind is offering all their advanced services and software to any new registering clinician.

About Genomind

Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind Professional PGx Express, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients mental health treatment. The Company also recently launched Genomind Mental Health Map a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at http://www.genomind.com.

(1) World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

(2) "Carbamazepine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

(3) This fraction of a percent represents the real world use HLA-A*31 types other than 31:01 (ie. HLA-A*31:04, 31:12, and 31:16) which may rarely cause false positive results. That being said, it is not known if these types are associated with skin disorders following use of carbamazepine.

Global Genomic Medicine Market to Witness Stellar Growth Rate in the Next 10 Years – Jewish Life News

Posted on July 6, 2020 by Danzig

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/11323

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/11323

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are

The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

Here is the original post:
Global Genomic Medicine Market to Witness Stellar Growth Rate in the Next 10 Years - Jewish Life News

The Formative Four: Top Health IT Capabilities That Will Improve Medication Management – Pharmacy Technology Report

Posted on September 3, 2020 by Danzig

Katherine CappsMolly Ekstrand, BPharm, BCACP, AE-C

Pharmacists well understand that medication is part of the daily lives of many Americans. In fact, studies show nearly 75% of visits to physician offices and hospital outpatient clinics involve medication therapy, and almost 30% of adults take five or more medications. Unfortunately, suboptimal medication use leads to at least 275,000 deaths annually and costs more than $528 billion.

Recently, our organization, The Get the Medications Right (GTMRx) Institute, in Tysons Corner, Va., released a report outlining steps for medication management reform, including a call for comprehensive medication management, or CMM. This comprehensive management is an evidence-based process of care that personalizes the approach, resulting in better care, reduced costs, and improved patient satisfaction and provider work life.

The report, the GTMRx Blueprint for Change, includes recommendations outlining how each stakeholder can get involved to improve patient carefrom physicians to clinical pharmacists, health plan sponsors, providers, consumer groups, employers as health plan sponsors, and policymakers.Many things need to change, but technology and information technology (IT) capabilities are central in the challenge for reform.

Here, we outline four health IT categories to achieve medication optimization through CMM, enabling a broad practice adoption of a systematic approach to medication use throughout the continuum of care. Software supports the practice management systems developed around CMM workflows and thought processes, driving consistency of the CMM service. Within each of these categories, organizations will undergo a journey toward maturity. However, considerations in each of these categories are foundational.

1. Clinical Decision Support Tools (at the point of care): Access to diagnostic results, clinical notes, patient status and other clinical information allows care teams to fulfill important activities in the CMM process. This information offers insight into patients experiencing medication therapy problems, and it helps the clinicians determine whether or not the patient has achieved the clinical goals of therapy. Having the ability to evaluate actual use patterns of all medications (e.g., over the counter, supplements, prescribed drugs and biologics) also is important. This full view of information is essential for the medication expert to properly assess each medication for appropriateness, focusing on the achievement of the clinical goals for each therapy. Organization and interpretation of these data in a medication-centric workflow can improve the efficiency and efficacy of clinical decision making. A medication-related dashboard should have the ability to support anyone on the care team, allowing them to make simple, streamlined decisions about a patients medication therapy. This dashboard should include objective data that help clinicians decide whether a patient needs a higher level statin, the blood pressure medicine should be increased, or pharmacogenomic data are needed to assess the safety or efficacy of the medications.

2. Population Health and Risk Stratification Tools: Health care resources are finite. There are certain patient populations that benefit more from CMM services. Tools that integrate data from electronic health records (EHRs), pharmacies, health plans and other reliable sources can provide the foundation for deployment of comprehensive risk models. Risk modeling tools allow payor, provider or value-based networks to easily identify the patients who are at risk and will benefit most from CMM services. Health systems, pharmacies, payors and prescribers should also have the ability to proactively reach out and invite at-risk patients to participate in CMM services, effectively automating a process and decreasing administrative burden from the point-of-care clinician.

3. Patient Engagement and Care Coordination Tools: Health IT should enable and facilitate the exchange of information between the patient and care team. Patients gather information in various forms that can inform clinical decisions regarding medication therapy. The tools should have the ability to integrate the digital therapeutic health information from a patient with the pharmacogenomic data that clinicians currently receive as a separate, cumbersome report. These types of information would come together in an EHR in a usable fashion. Health IT can facilitate bidirectional communication between the pharmacist, clinician and patient. Clinicians should have the ability to effectively and efficiently communicate across the continuum of care. In many cases, the patients care team, including the pharmacist providing comprehensive medication management, are not colocated and do not share a single EHR platform. Its imperative that health IT has the ability to enable bidirectional, secure health-related data exchange to promote optimal medication use.

4. Health IT Supporting Economic, Clinical and Humanistic Outcomes: Purpose-built software can drive consistency and demonstrate the value of CMM practice. Software ensures the capture of compliance and regulatory reporting requirements unique to CMM services. The tools should have the ability to allow the team to identify medication therapy problems in a systematic way, with the ability to gather and analyze information across systems and care settings. The tools should have the ability to track participation, offer point-of-care insight to the clinician, and, in order to efficiently identify medication therapy problems, record the defined medication care plan and steps toward resolution.

CMM services can be correlated with broader changes in health status or health care utilization patterns, thus demonstrating contribution and value to the broader health care system. However, optimizing medication use through CMM in practice truly and wholly relies on having the right data, at the right time, at the point of care and available to the entire team.

Ms. Capps is the co-founder and executive director of the GTMRx Instituteusvuwtdtxr, a catalyst for change that brings critical stakeholders together, bound by the urgent need to get the medications right. Ms. Ekstrand is a distinguished fellow at GTMRx.

See original here:
The Formative Four: Top Health IT Capabilities That Will Improve Medication Management - Pharmacy Technology Report

Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market – BioSpace

Posted on September 3, 2020 by Danzig

Transparency Market Research (TMR) has published a new report titled, Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.

Overview

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235

New Born Screening Segment to Dominate Global Genetic Testing Services Market

Request for Analysis of COVID19 Impact on Genetic Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10235

Oncology Segment Hold a Major Share of Global Genetic Testing Services Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=10235

Hospitals based laboratories Segment to Dominate Global Genetic Testing Services Market

North America to Dominate Global Genetic Testing Services Market

Buy Genetic Testing Services Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=10235&ltype=S

Competitive Landscape

The global genetic testing services market is consolidated in terms of number of players. Key players in the global Genetic Testing Services market include Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Genomic Health, Inc., NeoGenomics Laboratories, Inc, Eurofins Scientific, Ambry Genetics, Illumina, Inc, 23andMe, Inc., Exact Sciences, Natera, Invitae, Veracyte, and other prominent players.

Browse More Trending Reports by Transparency Market Research:

Nitinol Stents Market: https://www.transparencymarketresearch.com/nitinol-stents-market.html

Neurology Sterile Injectable Market: https://www.transparencymarketresearch.com/neurology-sterile-injectable-market.html

Microplate Systems Market: https://www.transparencymarketresearch.com/microplate-systems-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the rest here:
Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market - BioSpace

It’s Time to Cast a Wider Net With DPD Testing – Medscape

Posted on September 15, 2020 by Danzig

This transcript has been edited for clarity.

I'm David Kerr, professor of cancer medicine at the University of Oxford. One of my abiding interests has been to apply my old training in clinical pharmacology to how I deliver cancer medicine. I've been a cancer doc for 30 years and one of the recent roads I've traveled has been trying to incorporate pharmacogenetics into my clinical decision pathway. I'm a gastrointestinal oncologist; I treat patients predominantly with colorectal, gastric, and pancreatic cancers. Therefore, the fluoropyrimidines 5-fluorouracil (5-FU) and capecitabine are a central part of my therapeutic armamentarium.

I've talked before about the relevance of the pharmacogenomics of fluoropyrimidines and dihydropyrimidine dehydrogenase (DPD). This is a rate-limiting catabolic enzyme which is responsible for breaking down and destroying fluoropyrimidines. Therefore, it's terribly important. If we find genetic variance which reduces the activity of the enzyme, you get a concomitant increase in the plasma concentration of the 5-FU, and consequently much worse toxicity even to the point of death in some situations or extremely bad toxicity. This is compounded by the fact that 5-FU has nonlinear pharmacokinetics; that means for a small increase in dose you can get a very large increase in plasma concentration. It's a very complicated kinetic situation to be in.

We've instituted DPD testing in our institute in Oxford, I think successfully, and we're seeing a very significant change in reduction in the number of patients being admitted to wards with severe toxicity. I think DPD tests are very good at predicting life-threatening myelosuppression and risk of death, but they're not so good at fluoropyrimidine-induced diarrhea and mucositis.

One thing that interests me, and this is perhaps a more philosophical than scientific question, is how widely do we cast the ethnic net when we build a pharmacogenetic test? I do a lot of work in China. The single nucleotide polymorphisms (SNPs) we've discovered, based on our Western databases, don't apply as readily to our patients who are citizens of Eastern Asian countries.

I have many friends in the Middle East, having worked in Qatar, and I have very strong associations with colleagues in Saudi Arabia and the Middle East. We know that the Arab genome looks significantly different. Also, I work in sub-Saharan Africa, and the SNPs we see in DPD again have different frequencies and prevalences in the African population.

All of us live within a multiethnic society. Although patients in my hospital are predominantly Caucasian, it still seems to me important that we incorporate SNPs, which allow us to detect the possibility of these variants if we're seeing patients from Africa or from other ethnic groups. Rather than focusing and narrowing down in a very small SNP set, as is sometimes recommended, I would rather we had an expanded SNP set, especially in the time of next-generation sequencing when it's relatively easy to expand the SNP signature algorithm to include these different ethnic groups.

We have had a couple of Eastern African patients where, if we had not done the wider SNP that we helped to develop, we would have missed the possibility of being able to dose-reduce somebody who would undoubtedly have had life-threatening toxicity if we'd gone ahead with conventional treatment.

Why is that a philosophical question? So far, pharmacogenomics has been predominantly driven from the West in Caucasian populations. With precision medicine, of course, we understand that we can shape, change, or alter the SNP panel to suit one's local population an Arab SNP test, a Chinese SNP test, and so on. But if we live in a multiethnic society in which we serve a population of patients of many different ethnicities, shouldn't we have a pan test to cover the spectrum of these so that if we do have patients coming from different ethnic backgrounds, a single test with the appropriately wide SNP signature would serve all rather than some? Something to think about.

I would be very interested in your comments and I'd be very happy to engage in discussion about this. For the time being, Medscapers, over and out.

David J. Kerr, CBE, MD, DSc, is a professor of cancer medicine at the University of Oxford. He is recognized internationally for his work in the research and treatment of colorectal cancer and has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth II.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the original post:
It's Time to Cast a Wider Net With DPD Testing - Medscape

Pharmacogenomics Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2027 …

Posted on February 4, 2021 by Danzig

The major driving factors for the growth of this market in the North American region is the rising demand for personalized medicines, high medical reimbursement facilities, and technological advancement.

The Pharmacogenomics market analysis report ismainly focused on leading market players. Our analysts have provided information on financial statements of these players, product benchmarking, and their key business development strategies.

Claim Your FREE Sample Copy with Table of [emailprotected] https://www.emergenresearch.com/request-sample-form/88

Key participants include Abbott Laboratories, Admera Health, LLC, Agena Biosciences, Inc., Cancer Genetics, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd, geneOmbio Technologies Pvt Ltd., Genomic Health, Inc., Illumina, Inc., and Laboratory Corporation of America Holdings, among others.

Pharmacogenomics Market Overview:

The latest market study broadly segments the industry based on the product type range, application gamut, end-use industry, key regions, and the competitive background. One of the central components of the report is a detailed explanation of the gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and the financial standing of the leading market players. The developmental scope of the Pharmacogenomics markets new entrants and established companies has also been emphasized in the report.

Check Our [emailprotected]https://www.emergenresearch.com/select-license/88

Product and Services Outlook (Revenue, USD Billion; 2017-2027)

Products

Kits

Assays and Reagents

Instruments

Software

Services

Genotyping

SNP Identification

Pharmacogenetic Testing

Other Services

Technology Outlook (Revenue, USD Billion; 2017-2027)

Polymerase Chain Reaction (PCR)

Real-Time PCR

qPCR

Digital PCR

DNA Sequencing/Next Generation Sequencing (NGS)

Nucleic Acid Amplification Tests (NAATs)

Mass Spectrometry

Gel Electrophoresis

Hybridization

Fluorescence In Situ Hybridization (FISH)

Chromogenic In Situ Hybridization (CISH)

Others

Microarray

Others

Application Outlook (Revenue, USD Billion; 2017-2027)

Oncology

Infectious Diseases

Neurology/Psychiatry

Cardiovascular

Others

End-Use Outlook (Revenue, USD Billion; 2017-2027)

Research Organization

Pharmaceutical Companies

Diagnostic Centers

Others

In market segmentation by geographical regions, the report has analysed the following regions-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Click to access the Report Study, Read key highlights of the Report and Look at Projected [emailprotected] https://www.emergenresearch.com/industry-report/pharmacogenomics-market

Table of ContentChapter 1. Methodology & Sources1.1. Pharmacogenomics Market Definition1.2. Research Scope1.3. Methodology1.4. Research Sources1.4.1. Primary1.4.2. Secondary1.4.3. Paid Sources1.5. Pharmacogenomics Market Estimation TechniqueChapter 2. Executive Summary2.1. Pharmacogenomics Market Summary Snapshot, 2021-2028Chapter 3. Pharmacogenomics Market Key InsightsChapter 4.Pharmacogenomics Market Segmentation & Impact Analysis4.1.Pharmacogenomics Market Segmentation Analysis4.2. Pharmacogenomics Industrial Outlook4.2.1. Market indicators analysis4.2.2. Pharmacogenomics Market drivers analysis4.2.3. Pharmacogenomics Market restraints analysis4.3. Technological Insights4.4. Regulatory Framework4.5. Porters Five Forces Analysis4.6. Competitive Metric Space Analysis4.7. Price trend Analysis4.8. Covid-19 Impact Analysis

Click to access the Complete Pharmacogenomics Market ReportTable of Content: https://www.emergenresearch.com/industry-report/pharmacogenomics-market

Thank you for reading our report. Customization of the report is available as per client requirements. Kindly get in touch with us to know more about the report.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Explore our related report from different Publications:

Smart Irrigation Controllers MarketTo Be Worth USD 732.7 Million by 2027 Growing at a CAGR of 14.9% | Emergen Research

Soldier System Marketto Reach USD 15.19 Billion By 2027 Growing at a CAGR of 4.8% | Emergen Research

Plant-Based Food & Beverage Alternatives Marketto Reach USD 32.29 Billion By 2027 | Emergen Research

Nano Drones Marketto Reach USD 4.04 Billion By 2027 Growing at a CAGR of 26.8% | Emergen Research

Fermented Food and Ingredients MarketTo Be Worth USD 875.21 Billion by 2027 | Emergen Research

Signal Intelligence (SIGINT) Marketto Reach USD 18.28 Billion By 2027 | Emergen Research

Sodium Dichromate MarketTo Be Worth USD 1,242.4 Million by 2027| Emergen Research

Industrial Microbiology MarketTo Be Worth USD 17.71 Billion by 2027| Emergen Research

Surgical Instrument Tracking Systems MarketTo Reach USD 431.6 Million by 2027| Emergen Research

Medical Lighting Technologies MarketSize To Be Worth USD 2.99 Billion by 2027 | Emergen Research

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail:[emailprotected]

Facebook|LinkedIn|Twitter|Blogs

Continued here:
Pharmacogenomics Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2027 ...

How intelligent data transforms health in the time of COVID-19 – Mobihealth News

Posted on September 11, 2020 by Danzig

About the author:Dr. Liz Kwo is currently the staff VP of clinical data analytics at Anthem, and previously cofounded and served as CEO of telemedicine second opinion company InfiniteMD. She received anMDfrom Harvard Medical, an MBA from Harvard Business School and an MPH from the Harvard T.H. Chan School of Public Health.

COVID-19 has reshaped the way humans interact with technology in healthcare. Many countries have responded with public health measures such as social distancing, masks, and quarantine for suspected and confirmed cases.Intelligent data, technology, artificial intelligence (AI)and machine learning (ML) havestarted to lighten the burden to establish new ways for both health system supply and demand sustainability.

Among the most visible promoters of digital health arenext-generation payers and providers (NGPPs). These companies, many of them created after implementation of the Affordable Care Act (ACA), have commonly adopted the belief that technology is the solution to improving the healthcare system. Their focus is on delivering technology-enabled solutions to improve clients, such as employers' but more importantly, patients' as the end-user's experiences. These companies are using concepts such as blockchain, telehealth, web applications and genomics.

COVID-19 has prompted more healthcare organizations to embrace the idea of intelligent data as a tool for migration to digital health. Several companies are teaming up with startups that have the means to deliver technology-enhanced solutions either by allowing these startups to connect to their systems or by creating a customer-vendor type of relationship.

Connecting a smaller startup to a healthcare companys mainframe or command center means the startup involved in the process must codevelop solutions customized to the systems processes, flows, infrastructure and objectives. By accessing the companys platforms, whether a payor or provider through an electronic health record (EHR), a customer relationship management(CRM) system or other approach, the startup provides valid solutions based on the current status.

The solutions are not limited to identifying problems and providing fixes, but must extend to presenting innovations that enable the company to improve their patient records, deal more efficiently with aggregated and dispersed data, and handle a larger amount of information collected from various sources.

For example, collecting data run through predictive analytics via biometric devices that are connected remotely enables clinicians to complete their tasks at a higher speed with increased accuracy if the insights are actionable, potentially reducing medical costs if treatment or interventions can be determined correctly that arecustomized to the patient.

However, the downside of this type of cooperation is that it requires mobilization of massive internal resources, a relationship built on mutual trust and the willingness to share the risk among stakeholders such as providers, technology-enablement service companiesand payors. Therefore, health companies look to startup companiesfor innovative solutions that can be easily integrated in their workflows with ready-to-implement solutions, such as technology enabling remote consults between patients and care providers.

AI, for instance, requires multiple levels of mutual agreement between the healthcare companies and collaborative startups for processes such as data sharing privacy and security, liability protections, validation of models, and ongoing monitoring of progress and milestones. The implementation of AI in clinics has specific requirements, such as the availability of a workforce trained to use digital tools, remote access to the latest technologies, and knowledge and willingness from both clinicians and patients to adopt these tools.

AI has produced valuable techniques that are in place and will continue to improve in triaging care via chatbots, models for data integration that enable a better and faster illness prognosis, predicting illness progression through medical records, and detecting anomalies for fraud prevention in claims or to ensure proper claims payments.

Blockchain provides a change of secure and accurate information between nodes (e.g. patients, organizations andclinicians) with the help of a databasethat doesnt require control from a third party. Blockchain enables organizations to conduct trusted transactions and to reduce their administrative costs by sharing a common ledger instead of maintaining their own, separate data.

All the organizations participating in the blockchain have access to the shared data and can instantly protect it if accessed by unauthorized users. In the healthcare sector, blockchain is still in the early stages, and faces challenges such as the network effect, meaning that all parties sharing the blockchain must be willing to work together in testing and evaluating the advantages of this technology, which is easier said than done.

Deploying blockchain for provider access can mean that patients who are not able to find a doctor in their network can have access to a wider pool of physicians, hence benefiting from faster and improved access to care.

Telehealth (also referred to as e-health, mobile-healthor telemedicine) represents a means to remotely access medical services with the help of digital technologies such as laptops, smartphones and any mobile devices.

Among the objectives of telemedicine:

Examples of what telehealth can provide include:

Telehealth was used before COVID-19 in various formsas an instrument to train doctors in treating complex diseases in rural areas via video conference, such as the partnership between Medicaid and Extension for Community Healthcare Outcomes (ECHO) put in place at the University of Mexico,or as remote consultations with the use of symptom checkers defined by user inputs adopted in Spain by Mediktor.

COVID-19 brought a huge increase in Telehealth adoption. In the U.S., telehealth became used by 45% of consumers in COVID-19 era, compared to 11% of consumers in 2019 that called on this method to replace healthcare trips to the doctors office. Before the pandemic, the main players in the U.S. telehealth sector focused their services on urgent care areas by providing patients telehealth visits on demand. If before COVID-19 the estimated yearly revenues of U.S. telehealth companies were $3 billion, its estimated that in the next years up to $250 billion of current U.S. healthcare market could be invested in the virtualization of medical assistance through telehealth.

Telehealth, however, has its own challenges. Providers will need to adopt new ways of working;the exchange of concise and useful information must be improved;wider access and integration of technology is required;and clear data security measures must be in place. The effectiveness of telehealth compared to in-person visits will be closely measured, and reimbursement policies will have to be established and implemented properly.

For patients, the awareness and education of telehealth benefits must be understood, such as specific use cases to transmit valid information, the medical needs that telehealth can address, and understanding the insurance coverage of the service. These challenges can be surmounted, considering telehealth has the potential to bring benefits for patients, decrease costs for payers, increase efficiency for medical staffandimprove overall healthcare experience.

Web applications were developed as a response to the consumers expectations to have instant access to information. The healthcare market is currently dominated by two types of applications: ones that collect and record data regarding the health of clients (that can be shared with care providers and health insurance companies) and applications that provide access to health-related information such as health and wellness programs or provider and medical recommendations.

Mobile applications provided by some health insurance companies offer clients the opportunity to become more engaged in building their own team of healthcare providers, in order to compare prices of various services and to have autonomy in their overall health. With a few clicks, patients can locate providers inside and outside their network, choose an emergency room or urgent care center they need, or find a specialist that is available with a next-day appointment.

Many applications are populated with a huge database that delivers enormous amounts of informationin multiple languageson topics such as diseases, symptomsand medications, and are reviewed by prestigious medical professionals. Other applications are focused on prevention, helping people maintain good health by focusing them on behaviors such as motivational exercise or mindful eating, as in controlling consumption by documenting the foods they intend to eat and the impact on their health. They can calculate the caloric intake and compare foods to make better decisions.

Aside from the benefits brought to patients, web applications help providers collaborate with their patients. Applications that measure and monitor patient heart rates and blood sugar levels are equipped with triggers that send alerts when indicators reach a certain level. The alert is sent to the doctors that monitor those clients. Based on the reading and the medical history,the doctors can suggest a next step. As more people adopt these web applications, the tools will only become easier and faster to use as they improve over time.

The human genome, considered the blueprint of the human body, holds the potential biological plan for each individual. The link between a typical genome versus variants that may lead to disease can be established by analyzing a huge amount of medical records and genetic data. This is a complex, time-consumingmatching process.

The combined use of AI, machine learningand genomics brings to healthcare what has been missing in this discovery process: simplification and more accurate results in a lot shorter period of time. This can be achieved by integrating, for example, genomics with lab results, EHRs that include pathology, and imaging. T

This integration provides a more comprehensive look into a patient, which translates into better decisions taken by a supervising doctor andthe improved ability to forecast disease and to provide customized treatment and medication based on prediction patterns and the efficacy of a medication for the individual. By improving the ability to predict and treat, the costs of healthcare can be reduced by eliminating unnecessary lab tests or ineffective treatments.

The challenge in utilizing genomic data is translating this knowledge to real-world use cases. Pharmacogenomics is the use of genetic testing to inform medication-management decisions, which can improve patient outcomes and reduce health cost. For example, genomic data is used to determine treatment options for cancer patients.

This type of precision medicine creates a new consumer healthcare market for people to determine the influencing factors of their health, with extraordinary levels of treatment personalization across various chronic conditions. As patients ask their providers for advice and payers for coverage in this growing market, providers will need clear training to understand the right tests to order, how to interpret the results, and how to properly inform their patients about the results.

The costs of these tests have significantly decreased over time, but an adequate understanding of the benefits is required to achieve actionable insights from the results.

The progress made in intelligent data and AI use in the healthcare sector is surging. It is vital to ensure that all patients have access and affordable healthcare utilizing efficient tools and customized treatments that rely on intelligent data for groundbreaking innovations in healthcare.

Link:
How intelligent data transforms health in the time of COVID-19 - Mobihealth News

Pharmacogenomic (PGx) Testing Market to Witness Comprehensive Growth by 2018 to 2028 – The Daily Chronicle

Posted on September 15, 2020 by Danzig

Analysis of the Global Pharmacogenomic (PGx) Testing Market

A recent market research report on the Pharmacogenomic (PGx) Testing market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report sheds light on the different segments of the Pharmacogenomic (PGx) Testing market and provides a thorough understanding of the growth potential of each market segment over the forecast period (20XX-20XX).

According to the analysts at Fact.MR, the Pharmacogenomic (PGx) Testing market is evenly poised to register a CAGR growth of ~XX% during the assessment and surpass a value of ~US$ XX by the end of 2029. The report analyzes the micro and macro-economic factors that are likely to impact the growth of the Pharmacogenomic (PGx) Testing market in the upcoming years.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

Key Insights Enclosed in the Report

Segmentation of the Pharmacogenomic (PGx) Testing Market

The presented report dissects the Pharmacogenomic (PGx) Testing market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

COVID-19 Analysis

The report encompasses the major developments within the global Pharmacogenomic (PGx) Testing market amidst the novel COVID-19 pandemic. The report offers a thorough understanding of the different aspects of the market that are likely to be feel the impact of the pandemic.

Important doubts related to the Pharmacogenomic (PGx) Testing market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Follow this link:
Pharmacogenomic (PGx) Testing Market to Witness Comprehensive Growth by 2018 to 2028 - The Daily Chronicle

Global Pharmacogenomics Market Overview With Detailed Analysis, Competitive Landscape, Emerging Trends , Future Prospects during 2020-2027 – Scientect

Posted on September 15, 2020 by Danzig

The research report on Pharmacogenomics Market gives todays industry data and upcoming developments, allowing you to know the products and quit customers using sales rise and profitability of the market. The record gives a detailed analysis of key drivers, leading market key players, key segments, and regions. These understandings provided in the record would advantage market players to formulate strategies for the destiny and benefit a robust role within the worldwide market.

Click here to get a sample of the premium report:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#request_sample

Major Companies Covered in Research Report:

Bayer AGBecton, Dickinson and CompanyAffymetrix, Inc.F. Hoffmann-La Roche AGQIAGENAbbott Laboratories, Inc.Bio-Rad Laboratories, Inc.Thermo Fisher Scientific Inc.Illumina, Inc.AstraZeneca PLC

Regional segmentation of the Pharmacogenomics market:

The report also provides the latest market dynamics, industry news like mergers, acquisitions, and investments. The report can help to realize the market and strategize for business expansion accordingly. In the scheme analysis, it gives insights from marketing channel and market positioning to probable growth strategies, providing comprehensive analysis for new entrants or exists competitors in the Pharmacogenomics industry.

Get Upto 40% [emailprotected]

https://www.reportspedia.com/discount_inquiry/discount/58762

This detailed market study is centered on data obtained from multiple sources and is analyzed using various tools. These tools are engaged to achieve insights on the potential assessment of the industry, facilitating the market strategists with the latest development opportunities. Moreover, these tools also deliver a comprehensive analysis of each application/product segment in the global Pharmacogenomics Market.

Pharmacogenomics Market Segment considering Production, Revenue (Value), Price Trend by Type:

DNA SequencingMicroarray, Polymerase Chain ReactionElectrophoresisMass SpectrometryOthers

Pharmacogenomics Market Segment by Consumption Growth Rate and Market Share by Application:

Drug DiscoveryTailored TreatmentOncologyPain ManagementOther Therapeutic Applications

Inquire or Share Your Questions If Any before the Purchasing This Report

The key questions answered in Pharmacogenomics report:

Table of Content:

For Detailed TOC @

See the rest here:
Global Pharmacogenomics Market Overview With Detailed Analysis, Competitive Landscape, Emerging Trends , Future Prospects during 2020-2027 - Scientect

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: What Will COVID 19 Bring in Coming Days: F Hoffman La Roche, Agilent…

Posted on June 18, 2020 by Danzig

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

RequestSample PDF of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report https://www.worldwidemarketreports.com/sample/121299

F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH are some of the major organizations dominating the global market.

(*Note: Other Players Can be Added per Request)

Key players in the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market project before evaluating its feasibility. Overall, this report covers Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market report offers:

Regions Covered in This Report

Complete knowledge of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is based on the latest industry news, opportunities and trends in the expected region. The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the original post:
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: What Will COVID 19 Bring in Coming Days: F Hoffman La Roche, Agilent...

Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits – News- Graphic

Posted on July 2, 2020 by Danzig

COVINGTON, Ky., July 1, 2020 /PRNewswire/ --Gravity Diagnostics, a CLIA laboratory headquartered in Covington, Kentucky, today announced the U.S. Food and Drug Administration (FDA) has granted an update to their Emergency Use Authorization (EUA) to include use of nasal swab specimens that are self-collected by individuals using the Kroger Health COVID-19 Test Home Collection Kit. This was an addition to their earlier EUA that was granted on June 1st, 2020. The testing solution combines the safety and convenience of at-home specimen collection with the expert guidance of a Kroger Health clinician through video telehealth visit.

On March 16th, Gravity Diagnostics began processing COVID-19 samples with a vision to bring increased testing to their local communities, partnering with the Commonwealth of Kentucky to serve the healthcare facilities across the state and later with Kroger Health to bring more testing to Kentucky and nationwide via drive through testing sites. This next big step with Kroger Health will allow the two organizations to make a more widespread impact for COVID-19 testing across the nation, through an innovative method focused on quality, compliance, and patient experience.

Kroger Health will make the kits available to frontline associates across Kroger's Family of Companies based on medical need first, and will expand rapidly from there, with a goal of processing up to 60,000 per week by the end of July. Gravity Diagnostics to date has processed over 250,000 COVID-19 samples. The relatively small laboratory is evolving quickly to meet the need and scale through hiring of personnel and expansion of equipment and new laboratory space.

"Everything we have done during this time is with the people of our communities and nation in mind. After partnering with Kroger Health to execute their nationwide drive throughs, we were enthusiastic to continue to expand testing through our partnership in a way that is flexible and accessible during this critical time of working to reopen the United States," said Tony Remington, CEO of Gravity Diagnostics. "We are humbled to be a part of just one of the ways Kroger Health is executing a larger vision of how the healthcare industry is evolving."

About Gravity DiagnosticsGravity Diagnostics is a full-service state-of-the-art CLIA laboratory licensed in all 50 states providing innovative laboratory testing including Infectious Disease (Upper Respiratory and Sexually Transmitted), Toxicology, and Pharmacogenomics. We are an advocate for physicians, patients, and our communities, supporting them with unsurpassed integrity, regulatory compliance, and clinical expertise. Learn more by visiting gravitydiagnostics.com.

About Kroger Health:Kroger Health, the healthcare division of The Kroger Co., is one of America's leading retail healthcare organizations, with over 2,000 pharmacies and 200 clinics in 35 states serving more than 14 million customers. Their team of 22,000 healthcare practitioners - from pharmacists and nurse practitioners, to dietitians and technicians are committed to helping people live healthier lives. They believe in practicing at the top of our licenses and enabling "food as medicine" to help prevent or manage certain diseases. Learn more atwww.krogerhealth.com.

About The Kroger Co.:At The Kroger Co. (NYSE: KR), we are Fresh for Everyone and dedicated to their Purpose: ToFeed the Human Spirit. They are, across our family of companies, nearly half a million associates who serve over 11 million customers daily through a seamless shopping experience under a variety ofbanner names. They are committed to creating #ZeroHungerZeroWaste communities by 2025. To learn more about them, visit theirnewsroomand investor relationssite.

Contact: media@gravitydiagnostics.com

Original post:
Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits - News- Graphic

Covid 19 Analysis On Pharmacogenomics Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players Thermo Fisher Scientific Inc.,…

Posted on July 6, 2020 by Danzig

The strategy analysis on Global Pharmacogenomics Market gives insights of market size, trends, share, growth, development plans, Investment Plan, cost structure, and drivers analysis. With precise data covering all key aspects of the existing market, this report offers existing data of leading manufacturers. The Pharmacogenomics market report covers marketing channels and market positioning to potential growth strategies, providing in-depth analysis for new competitors or exists competitors in the Pharmacogenomics industry. The Report Gives Detail Analysis on Market concern Like Pharmacogenomics Market share, CAGR Status, Market demand, and up to date Market Trends with key Market segments. The report provides key statistics on the market status of the Pharmacogenomics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of the Pharmacogenomics market covering all important parameters.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Request A PDF Sample Copy Pharmacogenomics Market Report Click here: https://www.coherentmarketinsights.com/insight/request-pdf/1053

Global Pharmacogenomics market 2020-2026: Competitive Analysis

The Pharmacogenomics market report designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support. We provide a detailed analysis of key players operating in the global Pharmacogenomics market, including key players such as Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc.

Scope of Pharmacogenomics Market:

The Pharmacogenomics market was valued at XX Million US$ in 2020 and is projected to reach XX Million US$ by 2027, at a CAGR of XX% during the forecast period. In this study, 2020 has been considered as the base year and 2020 to 2027 as the forecast period to estimate the market size for Pharmacogenomics.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Pharmacogenomics Market which would mention How the Covid-19 is Affecting the Pharmacogenomics Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Pharmacogenomics Players to fight Covid-19 Impact.

The report also focuses on global major leading industry players of Global Pharmacogenomics market providing information such as company profiles, product picture, and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. With tables and figures helping analyze worldwide Global Pharmacogenomics market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position. The report provides detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Pharmacogenomics market. The Pharmacogenomics Market Report analyzes opportunities in the overall Pharmacogenomics market for stakeholders by identifying the high growth segments.

The scope of the report is limited to the application of the type and distribution channel. The regions considered in the scope of the report include North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC). This report presents the worldwide Pharmacogenomics market size (value, production, and consumption), splits the breakdown (data status 20152019 and forecast to 2027), by manufacturers, region, type, and application.

Market segment by Type, the product can be split into:Product Type Segmentation: Epicel, IntegraIndustry Segmentation: Chemical, Cosmetic, Pharmaceutical

The Global Pharmacogenomics Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Pharmacogenomics Market report.

The report comprehends precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Pharmacogenomics Market contenders and emerging new companies. The report uses SWOT analysis for the growth assessment of the outstanding Pharmacogenomics Market players. It also analyzes the most recent enhancements while estimating the expansion of the foremost Pharmacogenomics Market players. Additionally, the key product category and segments along with sub-segments of the global Pharmacogenomics Market are studied in the global Market research.

What Reports Provides

Full in-depth analysis of the parent market Important changes in market dynamics Segmentation details of the market Former, on-going, and projected market analysis in terms of volume and value Assessment of niche industry developments Market share analysis Key strategies of major players Emerging segments and regional markets Testimonials to companies in order to fortify their foothold in the market.

Further, in the research report, the following points are included along with an in-depth study of each point:

* Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered.* Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.* Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.* Other analyses Apart from the information, trade and distribution analysis for the Market, the contact information of major manufacturers, suppliers and key consumers is also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Reasons to Buy:

* Obtain the most up to date information available on the Pharmacogenomics projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Pharmacogenomics data.* Develop business strategies with the help of specific insights about the planned and announced Pharmacogenomics projects globally.* Keep abreast of key new-build Pharmacogenomics projects globally.* Assess your competitors planned and Pharmacogenomics projects and capacities.

Additionally, the report is joined by a vital examination of the Pharmacogenomics marketplace considering progress, part commitments, and future market forecasts. Furthermore, it offers detailed data of vendors including the profile, specifications of a product, sales, applications, annual performance in the industry, investments, acquisitions and mergers, market size, revenue, market share, and more. The report also studies individual regional market size along with country-wise and region-wise market size during the forecast period. The report also understands the export and import, production, and consumption of every particular region holding the highest market share, market size, or CAGR.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Note: *The discount is offered on the Standard Price of the report.

Enquire here get customization & check discount, please click: https://www.coherentmarketinsights.com/insight/request-discount/1053

If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

See the article here:
Covid 19 Analysis On Pharmacogenomics Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players Thermo Fisher Scientific Inc.,...

What You Need to Know About COVID-19 Testing – Touro College News

Posted on June 18, 2020 by Danzig

When you were at Roche, you developed an automated diagnostic testing platform that is now used for COVID-19 testing. Can you explain it?

The system is based on polymerase chain reaction, PCR for short, which uses a series of temperature cycles to make multiple copies of a specific DNA or RNA sequence. Early PCR testing required lots of human intervention, which limited its use outside of research settings. The system we developed can perform the necessary steps automatically, and can process 960 samples at once, with results in eight hours. The U.S. Food and Drug Administration has approved tests that run on the system for HIV, tuberculosis and many other pathogens, and approved a test for SARS-CoV-2, the virus that causes COVID-19, in mid-March.

What is an antibody test? Should anyone get one?

Also called serological tests, these check a persons blood for antibodies to COVID-19. If a person tests positive, they have been exposed to the virus, while a negative test means they havent been exposed. Public health authorities are now trying to perform as many antibody tests as possible, which gives them an idea of the level of exposure to the virus within the population.

How reliable is COVID testing and antibody testing?

COVID-19 testslike the Roche testare used to determine if a sick person has the virus. These test a sample thats taken by swab from the back of a persons throat, and are extremely reliable, as long as the sample was taken correctly. There have been problems with the reliability of antibody testing, largely because several products reached the market without FDA review.

How can someone be sure theyre getting a reliable test?

Ask if the test has been submitted for review to the FDA, and if it has been approved by the FDA. This is indicative of the comprehensiveness of the data supporting the validity of the test.

If I test positive, does that mean Im immune?

We still dont know whether people who make antibodies to COVID-19 will be immune to infection. Even if you have a positive antibody test, you should remain vigilant with social distancing and mask use.

Do you see a vaccine in the near future?

There is tremendous effort being dedicated to vaccine development in large global pharmaceutical companies as well as in biotechnology companies. I believe we will start to see a vaccine emerge by the end of this calendar year.

You hold more than 25 patents. Of which are you most proud?

Probably the early ones that focused on identifying variation in the human genome. The early work on DNA identity has served as the foundation for the exciting field of pharmacogenomics, which explores how genes affect drug response.

What did you do before coming to Touro?

I was a senior executive in the pharmaceutical / biotechnology industry. I was also involved in several biotechnology start-ups and held an adjunct appointment at Touros New York Medical College.

Link:
What You Need to Know About COVID-19 Testing - Touro College News

Global Strategic Analysis of the Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2020-2025 – GlobeNewswire

Posted on June 18, 2020 by Danzig

Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report has been added to ResearchAndMarkets.com's offering.

This comprehensive report examines the precision medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, targeted therapeutics, companion diagnostics, and the associated market environment.

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany, and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures.

The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the personalized therapeutic and associated companion diagnostic market have huge opportunities for growth. This industry is revolutionizing the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments.

The report is supported by over 360 tables & figures over 470 pages. The personalized medicine market is presented as follows:

A wealth of financial data & business strategy information is provided including:

SWOT, Economic & Regulatory Environment specifics include:

This report highlights a number of significant players and influential company's and gives details of their operations, products, financials and business strategy:

For more information about this report visit https://www.researchandmarkets.com/r/qmotdw

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Here is the original post:
Global Strategic Analysis of the Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2020-2025 - GlobeNewswire

Genetics and Pharmacology | YourHub – The Know

Posted on June 18, 2020 by Danzig

Ever had a bad experience with a prescription?

Ever thought it was an allergic reaction to a medication?

In 2017 I had a significant abdominal surgery that required me to take pain medication, anti-inflammatories, and antibiotics. The surgery was supposed to help with a significant abdominal umbilical hernia. It occurred on a Wednesday, and by Monday, I was having a significant reaction to the pain medication, where my FACE went NUMB. Talk about scary.

Leading up to the surgery, I had taken part in 2 appointments where I discussed previous bad reactions to the pain medication and talked about my concerns. They told me it was a necessary evil in this case so that I could sleep. The morning of surgery, after long discussion with the anesthesiologist, He asked if I had testing done to look at my response to different drugs. At that time, I didnt even know that was a thing that could be done.

The news media and medical media lately has talked a lot about epigenetics and epigenomics and we are starting to hear about pharmacogenetics. Pharmacogenetics can be done through DNA testing to specifically look at your genetics and how they might react to specific types of drugs. They can allow for better dosing, better drug choice so there is less guess work, and overall better outcomes. Pharmacogenetics can also help in looking at how some people may become addicted and others not to things like marijuana, which the Prop 64 group in Colorado would have us believe is not possible.

Pharmacogenetics can also let us know when it might be time to change a drug, because the epigenetics/epigenomics, or the environmental factors that cause the genes to change may have been affected over long-term use of specific drugs. These drugs can be related to addiction treatment, pain management, mental health disorders (bipolar, schizophrenia, depression), autoimmune logical drugs including chemotherapy.

Along the line of epigenetics/epigenomics, there is a specific testing that can be done that supports your DNA sections. It looks at what will optimally support your health, and with that information we can create a supplement that is SPECIFIC to you. Repeating the test about 6 months after initial testing and consuming of those supplements is recommended due to the changes you could potentially make. Then every year.

Why would you need a DNA-specific supplement? Colorado has one of the highest levels of radiation exposure in the continental U.S. Specifically, we have a lot of naturally occurring uranium and radon. Both of those are known carcinogens. Also, think about how much and what type of sunscreen you apply every year in Colorado while enjoying the outdoor lifestyle you love. Chemical barriers are more likely to interact with the radiation from the sun to create mutation of cells. It starts at the skin level, but quickly spreads to the body as the skin is an organ that ABSORBS things you put on it.

If you have questions about how DNA testing can improve your health, life and longevity, dont hesitate to reach out!

References:

*https://dnalife.academy/dna-health/

*Recent developments in genetic/genomic medicine, Rachel H. Horton and Anneke M. Lucassen, Clin Sci (Lond). 2019 Mar 15; 133(5): 697708.Published online 2019 Mar 5. Prepublished online 2019 Feb 27. doi: 10.1042/CS20180436

*Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry; Azmeraw T. Amare,1 Klaus Oliver Schubert,1,2 and Bernhard T. Baune1; EPMA J. 2017 Sep; 8(3): 211227.Published online 2017 Sep 5. doi: 10.1007/s13167-017-0112-8*Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants; Ramn Cacabelos,1,2,* Luca Fernndez-Novoa,1,2 Roco Martnez-Bouza,1,2 Adam McKay,1,2 Juan C. Carril,1,2 Valter Lombardi,1,2 Lola Corzo,1,2 Ivn Carrera,1,2 Ivn Tellado,1,2 Laura Nebril,1,2 Margarita Alcaraz,1,2 Susana Rodrguez,1,2 ngela Casas,1,2 Vernica Couceiro,1,2 and Antn lvarez1,2Pharmaceuticals (Basel). 2010 Oct; 3(10): 30403100.Published online 2010 Sep 29. doi: 10.3390/ph3103040*Some observations on the role of environment and genetics in behaviour of wild and domestic forms of Sus scrofa (European wild boars and domestic pigs)S Robert, J Dancosse, A Dallaire Applied Animal Behaviour Science, 1987 Elsevier

Global Hematology Analyzer Market Future Growth Analysis, Business Demand And Opportunities To 2026|VirtualExpo, Drucker Diagnostics, EKF DIAGNOSTICS…

Posted on June 12, 2020 by Danzig

Some of the major companies functioning in global hematology analyzer market are Abbott, Beckman Coulter Inc, HORIBA Ltd, Siemens, Sysmex, NIHON KOHDEN CORPORATION, Bio-Rad Laboratories inc, Johnson & Johnson, Thermo Fisher Scientific,BD, F. Hoffmann-La Roche Ltd, Boule Diagnostics AB., Danaher, Diatron, Erba Diagnostics, Inc., VirtualExpo, Drucker Diagnostics, EKF DIAGNOSTICS HOLDINGS PLC, Ortho Clinical Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co, Ltd and Biosystems S.A among others

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hematology-analyzer-market

Have look on the Premium Insights of the Report

Segmentation:Global Hematology Analyzer Market

By Product and Services

(Hematology Products & Services, Hemostasis Products & Services, Immunohematology Products & Services),

Price Range

(High-End Hematology Analyzers, Mid-Range Hematology Analyzers, Low-End Hematology Analyzers),

End User

(Hospital Laboratories, Commercial Service Providers, Government Reference Laboratories, Research and Academic Institutes),

Geography

(North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Market Drivers

Market Restraints

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hematology-analyzer-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

Excerpt from:
Global Hematology Analyzer Market Future Growth Analysis, Business Demand And Opportunities To 2026|VirtualExpo, Drucker Diagnostics, EKF DIAGNOSTICS...

Qualitative Analysis and Competitive Industry Scenario of Pharmacogenomics Market – Medic Insider

Posted on June 12, 2020 by Danzig

Prophecy Market Insights Pharmacogenomics market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges. The research report study offers keen competitive landscape analysis including key development trends, accurate quantitative and in-depth commentary insights, market dynamics, and key regional development status forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Pharmacogenomics market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Segmentation Overview:

PharmacogenomicsMarket Key Companies:

Thermo Fisher Scientific Inc., Qiagen N.V., F.Hoffmann-La Roche AG, Abbot Laboratories, Diatech Pharmacogenetics, and Assurex Health Inc.

The Pharmacogenomics research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Pharmacogenomics market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/244

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. This report is a must-read for investors, entrepreneurs, consultants, researchers, business strategists, and all those who have any kind of stake or are planning to foray into the Pharmacogenomics industry in any manner.

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://atransportation.blogspot.com/

Continue reading here:
Qualitative Analysis and Competitive Industry Scenario of Pharmacogenomics Market - Medic Insider

Global Pharmacogenomics (PGx) Market 2020 Future Analysis, Current Trends and Forecast with COVID-19 After Effects – Flagler Times

Posted on May 29, 2020 by Danzig

Global Pharmacogenomics (PGx) Market 2020 by Company, Type and Application, Forecast to 2025 is an analysis from Researchstore.biz is based on past information and future opportunities in the global market. The report covers many aspects of the industry like the market size, market status, market trends and forecast from 2020 to 2025. Information on the competitors and the specific growth opportunities with key market drivers has been provided. The report estimates revenue, production, consumption, sales, suppliers, manufacturers, countries, types, and applications. It also shows a regional growth status by analyzing all of the areas and worldwide locations of the global Pharmacogenomics (PGx) market covering market length, volume, and value, as well as price facts.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/36456

The report also goes into the past for analyzing the market scenario, where it found various aspects such as segmentation, landscape analysis, developments, product types, and applications. All the key industry players are covered combined with their company profiles, size, production value, product specifications, capacity and 2020-2025 market shares occupied by each company. Additionally, their contact information, product specifications, company profiles, and production value has been provided. It represents a future outlook prospect on different factors driving or prohibiting global Pharmacogenomics (PGx) market growth.

The key companies in the global industry include- Abbott Laboratories , Myriad Genetics, Inc. , Astrazeneca , Affymetrix, Inc. , Laboratory Corporation of America Holdings , Assurex Health, Inc , Pfizer, Inc , Illumina, Inc. , GeneDX , Pathway Genomics , Transgenomic, Inc. , Qiagen, Inc. , Thermo Fisher Scientific , Rocheg , Teva Pharmaceutical Industries Ltd.

Segmentation by product type and analysis of the market: olymerase Chain Reaction (PCR), Microarray, Sequencing, Other, etc.

Segmentation by application and analysis of the market: ardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, Other, etc.

Analysis of The Regional Expanse:

Geographically the market report is divided into some major key regions, with sales data, revenue data (Million $$ USD), share data and growth rate of the industry for mentioned regions. This Pharmacogenomics (PGx) market report offers examination and growth of the market in these districts covering North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-pharmacogenomics-pgx-market-36456

Moreover, the report encompasses valuable advice and direction for businesses and individuals, estimating global Pharmacogenomics (PGx) market development trends, current market dynamics, upstream raw materials, and downstream demand. Overall report documents leading growth status, segmentation, landscape analysis, developments, product types, and applications.

There are 15 Chapters to Deeply Display the Global Pharmacogenomics (PGx) Market.

Chapter 1, to describe Pharmacogenomics (PGx) market introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to track the top manufacturers with sales, revenue, and price in 2019 and 2020;

Chapter 3, to analyze the competitive situation among the top manufacturers, with sales, revenue, and market share in 2019 and 2020;

Chapter 4, to show the global market by regions, with sales, revenue, and market share of for each region, from 2015 to 2020;

Chapter 5, 6, 7, 8 and 9, to study the market by countries, by type, by application, and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;

Chapter 12, market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025;

Chapter 13, 14 and 15, to assess sales channel, distributors, traders, dealers, research findings and Conclusion, appendix and data source

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@researchstore.bizWeb: http://www.researchstore.biz

Originally posted here:
Global Pharmacogenomics (PGx) Market 2020 Future Analysis, Current Trends and Forecast with COVID-19 After Effects - Flagler Times

Green Shield Canada invests in TELUS and TYDO backed GenXys – Private Capital Journal

Posted on May 29, 2020 by Danzig

Green Shield Canada (GSC) has made an investment in GenXys Health Care Systems Inc. Financial terms were not disclosed.

Vancouver based GenXys Health Care Systems is a provider of comprehensive precision prescribing software. GenXys precision prescribing software and pharmacogenetic solutions prevent adverse drug reactions, a leading cause of death in developed countries, and personalize drug selection to increase drug efficacy.

Green Shield Canada and GenXys will collaborate on new pharmacogenomics products set to launch later this year with a focus on driving more informed prescribing, fewer adverse drug reactions and better health outcomes for patients.

GenXys Health Care Systems is backed by Telus Ventures and Chinese incubator company JiuHui TYDO (), having raised $1.77 million seed funding in 2018.

photo credit: GenXys

News Release

Green Shield Canada invests in GenXys to harness power of pharmacogenomics

TORONTO, May 26, 2020 (GLOBE NEWSWIRE) With the concept of personalized medicine gathering momentum across the health care environment, Green Shield Canada (GSC) is pleased to announce an investment in GenXys, a Canadian pharmacogenomics leader, to leverage the value of tailoring drug treatment to a persons total health profile including their genetic makeup.

The two companies will be collaborating on new pharmacogenomics products set to launch later this year with a focus on driving more informed prescribing, fewer adverse drug reactions and better health outcomes for patients.

GenXys stood out as a forward-thinking partner that shared our commitment to solving complex health challenges, explains David Willows, GSCs EVP, Digital, Innovation and Brand Experience. GSC has a long history of measuring the value of health benefits spending, and we look forward to exploring the role of pharmacogenomics in maximizing patient health outcomes and advancing the specific value of drug spend.

We are excited to be working with the GSC team as we shape the next stages of the pharmacogenomics story, says Karl Pringle, GenXys CEO. Our partnership opens the door to a wide range of new possibilities.

This investment comes on the heels of a groundbreaking study conducted by GSC and HBM+ (its health benefit management solutions division) on the impact of pharmacogenomics on more than 200 outpatients who had been diagnosed with major mental health conditions, including depression and anxiety.

The full study results will be shared later this summer, but one key finding stands out those patients receiving pharmacogenomics-guided treatment reported significantly greater improvements over a six-month period across a range of clinical outcome measures, including severity of depression and anxiety as well as level of disability.

We had always felt that the key unanswered question was whether clinician access to pharmacogenetic test results would improve patient outcomes, adds Willows. This study clearly showed that it can, strengthening our belief in the impact of pharmacogenomics-guided treatments.

For more information:GSC Media Department1.800.268.6613 ext. 3409media@greenshield.ca

About Green Shield Canada (GSC)

GSC is Canadas fourth-largest health and dental benefits provider, and is uniquely structured as a social enterprise with the purpose of making it easier for people to live their healthiest lives. From coast-to-coast, our service delivery includes drug, dental, extended health care, vision, hospital, and travel benefits for groups and individuals, as well as administration and benefits management services. Supported by outcomes-based sustainability strategies, advanced technology, and exceptional customer service, GSC creates innovative programs for nearly four million plan participants nationwide. greenshield.ca

Ted is the architect of CVCA infobase, and is the architectof CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.

More:
Green Shield Canada invests in TELUS and TYDO backed GenXys - Private Capital Journal

Select Page ::